European Heart Journal Advance Access originally published online on August 17, 2005
European Heart Journal 2005 26(23):2524-2528; doi:10.1093/eurheartj/ehi459
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
1Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S Limestone, 326 Wethington Building, Lexington, KY 40536-0200, USA
2Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
3Hôpital Cardiologique, Lille, France
4Skejby Hospital, Aarhus University Hospital, Brendstrupgaardsvej, Denmark
5University of Pennsylvania Medical Center, Philadelphia, PA, USA
6Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
7Riverside Methodist Hospital, Columbus, OH, USA
8Jean-Minjoz Hospital, Besançon, France
9Columbia University Medical Center, New York, NY, USA
10Università Degli Studi di Parma, Parma, Italy
Received 12 May 2005; revised 30 June 2005; accepted 25 July 2005; online publish-ahead-of-print 17 August 2005.
* Corresponding author. Tel: +1 859 323 5630; fax: +1 859 257 6475. E-mail address: mukherjee{at}uky.edu
Aims Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population.
Methods and results In 18 countries at 149 hospitals, 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72–1.67; P=0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64–1.67; P=0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56–3.13; P=0.530).
Conclusion At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab.
Key Words: Glycoprotein IIb/IIIa inhibitor • Tirofiban • Abciximab • Mortality • Percutaneous coronary intervention
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A. W.J. van 't Hof, G. Campo, C. Hamm, J. ten Berg, L. Bolognese, F. Saia, G. B. Danzi, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur. Heart J., September 14, 2009; (2009) ehp376v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bode and K. Huber Antiplatelet therapy in percutaneous coronary intervention Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A13 - A20. [Abstract] [Full Text] [PDF]
|
|